A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Newer entrants to the pharmacy benefit management market will continue to face stiff competition in 2025 as they seek more ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...